savvyHEALTH.com: - FDA Warns Against Using Common Antihistamine








We are a safe place to discuss your personal health issues.


Sign up for free!



  Login:

  Password:



Sign up for free email!


Using a Peak Flow Meter
Using a Peak Flow Meter


(More Video)

Online learning resources for diabetes, asthma, hypertension, and nutrition.
Diabetes 101: Learn more about diabetes, managing your blood sugar levels, and your diet.
Diabetes 201: Learn more about diabetes, managing your blood sugars, and your diet.
Asthma 101: Learn more about asthma and dealing with shortness of breath.
Hypertension 101: Learn more about hypertension and managing your blood pressure.
Nutrition 101: Learn more about improving your nutrition and diet

"Do or do not. There is no try."
~Yoda, The Empire Strikes Back

Help me learn about:
Google
Web savvyhealth.com

We welcome all suggestions. Please tell us how to make savvyHEALTH even better.


Health News

FDA Warns Against Using Common Antihistamine

      WASHINGTON (AP) - The Food and Drug Administration warned Americans Monday not to use dozens of over-the-counter cold remedies or appetite suppressants until their makers replace an ingredient that could cause hemorrhagic strokes, especially in young women.

      The ingredient, called phenylpropanolamine or PPA, is found in products ranging from Dexatrim to Triaminic.

      The FDA said it is taking steps to formally ban PPA, but meeting the legal requirements will take a few months. So meanwhile, the agency wrote manufacturers asking them voluntarily to immediately quit selling products containing the ingredient.

      At least one manufacturer told retailers Monday to remove a PPA-containing cold remedy, Contac 12-hour Cold Capsules, from store shelves. Five other versions of Contac contain an alternative ingredient, pseudoephedrine, that is safe, stressed manufacturer SmithKline Beecham Consumer Healthcare. It urged consumers to call a hot line if they''re confused about the risk.

      The risk of a hemorrhagic stroke, or bleeding in the brain, is very small to an individual user. But with millions of Americans swallowing PPA every day, the FDA determined the ingredient could be to blame for 200 to 500 strokes just in people under age 50 - those who typically are too young to be at risk for strokes.

      ``We suggest you stop taking the drug immediately and use an alternative,'' says an FDA warning issued for consumers Monday.

      Consumers should check the ingredient list of all nonprescription cold relievers for PPA and avoid those products, the FDA said. Instead, they could use cold pills containing the ingredient pseudoephedrine, or use nasal sprays.

      However, PPA is the only nonprescription diet ingredient on the market. There are prescription weight-loss drugs, so dieters should consult their physicians about their options, said FDA nonprescription drugs chief Dr. Charles Ganley.

      Drug manufacturers had fought the FDA''s decisions, arguing that concern over the decades-old ingredient was overblown. But in a public hearing less than three weeks ago, FDA''s scientific advisers dealt manufacturers a blow by voting unanimously that PPA is unsafe.

      Drug companies were scrambling Monday to decide how to react to FDA''s request. The maker of the largest-selling nonprescription diet pill, Dexatrim, Chattem Inc., refused comment.

      Hemorrhagic strokes, while the least common type of stroke, often are deadly and can leave survivors disabled. They are very rare in people under age 50; the risk rises with age, as well as with high blood pressure, smoking, alcohol and use of blood-thinning medicines.

      Doctors'' first warning sign about PPA came in the 1980s when medical journals cited several dozen puzzling cases of young women who suddenly had strokes within days of taking appetite suppressants.

      The FDA''s own records show 44 cases of hemorrhagic stroke among PPA users in the past 30 years. Most were women; the median age was 35.

      But the drug industry successfully argued more research was needed to prove if PPA was to blame. So the Consumer Healthcare Products Association funded a five-year study by Yale University comparing 702 hemorrhagic stroke survivors under 50 with 1,376 similar ``controls'' who had never suffered a stroke. The goal was to see if PPA use was more common among stroke sufferers than among healthy people.

      The study found PPA increases stroke risk for young women - not men - under two circumstances: within three days of taking PPA-containing appetite suppressants, or within three days of taking their first-ever PPA dose for any reason.

     

Copyright 2000 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.




About savvyHEALTH | Privacy | Feedback | Home

http://www.savvyHEALTH.com/

All contents copyright © 1999-2017 savvyHEALTH, Inc. All rights reserved.

This internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health, you should always consult with a physician or other healthcare professional. Please review the Terms of Use before using this site. Your use of the site indicates your agreement to be bound by the Terms of Use.